Introduction: Different endotypes of rhinitis are known, but its pathomechanism has not been conclusively established. For example, the precise difference between systemic allergic rhinitis (SAR) and local allergic rhinitis (LAR) is still being checked. Comparison of patients with LAR and with allergies to birch of those with intermittent allergic rhinitis, same allergy, or with non-allergic rhinitis (NAR) was the purpose of this study. Methods: Twenty-six patients with LAR, 18 with SAR and allergy to birch, and 21 with NAR were included. Patients who met the inclusion criteria were selected to undergo the following procedures at baseline: medical examinations, nasal provocation test (NPT), detection of nasal-specific IgE to birch as well as basophil activation test (BAT). All immunological parameters were detected before and after NPT. Results: Concentration of nasal IgE to Bet v1 increased comparably in the LAR and SAR groups after NPT to birch as follows: in 21 (81%) patients with LAR, 14 (78%) with SAR, and in everyone in the NAR group. Serum concentration of allergen-specific IgE to Bet v1 increased significantly from a median of 20.7 (25–75% interval: 11.2–35.6) IU/mL to 29.9 (13.6–44.1) (p = 0.028) after NPT in patients with SAR. Allergen-specific IgE to Bet v1 was absent in all patients with LAR and NAR before and after NPT. BAT with Bet v1 was positive in 22 (85%) patients with LAR, in 14 (78%) with SAR, and 2 (9.5%) with NAR. Conclusion: These obtained data suggest there are no potential mechanisms that could explain LAR compared to SAR.
Int Arch Allergy Immunol

中文翻译：

---

桦木花粉引起的局部和全身性过敏性鼻炎之间的潜在差异。

简介：鼻炎的内型不同，但其致病机理尚未完全确定。例如，仍在检查全身性变应性鼻炎（SAR）与局部变应性鼻炎（LAR）之间的确切差异。本研究的目的是比较患有LAR且对桦树过敏的患者与间歇性过敏性鼻炎，相同过敏或非过敏性鼻炎（NAR）的患者。方法：包括26例LAR患者，18例SAR和桦木过敏患者以及21例NAR患者。选择符合入选标准的患者在基线时接受以下程序：体格检查，鼻腔激发试验（NPT），鼻腔桦木特异性IgE检测以及嗜碱性粒细胞活化测试（BAT）。在NPT之前和之后检测所有免疫学参数。结果： NPT到桦树后，LAR和SAR组的鼻IgE浓度在Bet v1上相对增加，如下所示：在21例（81％）LAR患者中，14例（78％）SAR患者以及NAR组中的所有人。Bet v1的变应原特异性IgE的血清浓度从中值20.7（25–75％区间：11.2–35.6）IU / mL显着增加至29.9（13.6–44.1）（p= N = 0.028）SAR患者。在NPT之前和之后，所有LAR和NAR患者均没有针对Bet v1的变应原特异性IgE。Bet v1的BAT在LAR患者中为22（85％），在SAR患者中为14（78％），在NAR中为2（9.5％）。结论：这些获得的数据表明，与SAR相比，没有任何潜在的机制可以解释LAR。
Int Arch过敏免疫